US FDA approves novel treatment for Ebola

22 December 2020
fda_big

Miami, USA-based Ridgeback Biotherapeutics has won US regulatory approval for a new Ebola virus treatment, Ebanga (ansuvimab-zykl).

The monoclonal antibody works by blocking binding of the Zaire ebolavirus to the cell receptor, preventing its entry into the cell.

Zaire ebolavirus is one of six variants of the rare but severe, often fatal illness, which has flared up multiple times in African countries since it was discovered in 1976.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology